套细胞淋巴瘤预后分层

Prognostic stratification in patients with mantle cell lymphoma

套细胞淋巴瘤（MCL）是一种特殊类型的侵袭性B细胞非霍奇金淋巴瘤（NHL）,占NHL的5%~10%,老年患者多见,男性明显多于女性,预后差。近年来,大剂量化疗、利妥昔单抗的应用临床和造血干细胞移植的开展,改善了MCL患者的生存。新药如苯达莫司汀、硼替佐米、来那度胺、Ibrutinib及m TOR抑制剂等的疗效令人鼓舞。而MCL国际预后指数（MIPI）的提出,使MCL有了独立的预后评价系统,有利于更好的分层治疗。

Mantle cell lymphoma（MCL）is a specific B-cell non-Hodgkin＇s lyrnphoma（NHL） with an aggressive clinical course. MCL accounts for about 5-10% of all NHL cases,the majority of which are elder patients.The patients are predominantly men with poorer prognosis. In recent years,the application of new therapeutic paradigms,including rituximab,high-dose cytarabine and stem cell transplantation,has dramatically improved the outcome of the patients with MCL. The introduction of new drugs,including benda mustine, lenalidomide, ibrutinib and mTOR inhibitor, has already led to new perspectives in patient.Concurrently, the International Prognostic Index of MCL（MIPI）,as a new prognostic model,has been established to predict the survival outcome and make the patients with MCL receive a better stratified treatment strategy.